Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report.

Created on 29 Aug 2026

Authors

Gabriel B Rashba, Lucas Kaplan, David Bolos, Armine Baltayan, Simon Backer

Published in

Cureus. Volume 18. Issue 7. Pages e113596. Epub Jul 29, 2026.

Abstract

Neuroendocrine carcinoma is a rare, biologically diverse malignancy that frequently presents with metastatic disease, which can carry a poor prognosis. Its symptomatology is often nonspecific, resulting in delayed diagnosis with substantial tumor burden. Platinum-based chemotherapy remains the cornerstone of treatment, although outcomes remain poor and novel therapeutic strategies are needed. We report a case of newly diagnosed metastatic neuroendocrine cancer in a patient presenting with vague constitutional and gastrointestinal symptoms, ultimately complicated by impending hepatic failure from extensive liver involvement. Initial evaluation raised greater concern for lymphoma or thyroid malignancy, given the pattern of lymphadenopathy and imaging findings. However, tissue biopsy ultimately revealed metastatic neuroendocrine carcinoma. This case underscores the aggressive nature of the poorly differentiated neuroendocrine carcinoma subtype, the importance of early recognition, and the challenges of managing patients with rapidly progressive disease.

PMID:
42666762
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement